WO1993018769A3 - A new use of quinazoline derivative - Google Patents
A new use of quinazoline derivative Download PDFInfo
- Publication number
- WO1993018769A3 WO1993018769A3 PCT/JP1993/000307 JP9300307W WO9318769A3 WO 1993018769 A3 WO1993018769 A3 WO 1993018769A3 JP 9300307 W JP9300307 W JP 9300307W WO 9318769 A3 WO9318769 A3 WO 9318769A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- alkyl
- hydroxy
- protected
- prolactin
- optionally substituted
- Prior art date
Links
- 125000002294 quinazolinyl group Chemical class N1=C(N=CC2=CC=CC=C12)* 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- -1 nitro, amino, protected amino, hydroxyamino Chemical group 0.000 abstract 3
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- 206010003210 Arteriosclerosis Diseases 0.000 abstract 1
- 206010007572 Cardiac hypertrophy Diseases 0.000 abstract 1
- 208000006029 Cardiomegaly Diseases 0.000 abstract 1
- 208000010445 Chilblains Diseases 0.000 abstract 1
- 206010011703 Cyanosis Diseases 0.000 abstract 1
- 208000002249 Diabetes Complications Diseases 0.000 abstract 1
- 206010012655 Diabetic complications Diseases 0.000 abstract 1
- 208000005189 Embolism Diseases 0.000 abstract 1
- 208000001034 Frostbite Diseases 0.000 abstract 1
- 208000001287 Galactorrhea Diseases 0.000 abstract 1
- 206010017600 Galactorrhoea Diseases 0.000 abstract 1
- 206010018265 Gigantism Diseases 0.000 abstract 1
- 206010020571 Hyperaldosteronism Diseases 0.000 abstract 1
- 206010020852 Hypertonia Diseases 0.000 abstract 1
- 206010020880 Hypertrophy Diseases 0.000 abstract 1
- 208000011707 Ovulation disease Diseases 0.000 abstract 1
- 208000015875 Pituitary gigantism Diseases 0.000 abstract 1
- 102000003946 Prolactin Human genes 0.000 abstract 1
- 108010057464 Prolactin Proteins 0.000 abstract 1
- 206010036831 Prolactin-producing pituitary tumour Diseases 0.000 abstract 1
- 208000001647 Renal Insufficiency Diseases 0.000 abstract 1
- 208000001871 Tachycardia Diseases 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 125000004414 alkyl thio group Chemical group 0.000 abstract 1
- 125000002947 alkylene group Chemical group 0.000 abstract 1
- 208000011775 arteriosclerosis disease Diseases 0.000 abstract 1
- 125000003118 aryl group Chemical group 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 1
- 239000001257 hydrogen Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical class [H]* 0.000 abstract 1
- 201000006370 kidney failure Diseases 0.000 abstract 1
- 201000008383 nephritis Diseases 0.000 abstract 1
- 230000000414 obstructive effect Effects 0.000 abstract 1
- 201000009395 primary hyperaldosteronism Diseases 0.000 abstract 1
- 229940097325 prolactin Drugs 0.000 abstract 1
- 201000002140 prolactin producing pituitary tumor Diseases 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000001424 substituent group Chemical group 0.000 abstract 1
- 230000002889 sympathetic effect Effects 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 230000006794 tachycardia Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
A use of a compound of formula (I) in which R?1 and R2¿ are each hydrogen, halogen, nitro, amino, protected amino, hydroxyamino, lower alkyl, hydroxy, protected hydroxy, sulfamoyl, carboxy, protected carboxy, mercapto, optionally substituted heterocyclic-carbonyl, optionally substituted heterocyclic-(lower)alkyl, lower alkylthio, hydroxy(lower)alkyl or protected hydroxy(lower)alkyl, R3 is aryl which may have suitable substituent(s), and A is lower alkylene, or a pharmaceutically acceptable salt thereof, for the treatment of various diseases selected from the group consisting of cardiac hypertrophy, nephropacy such as nephritis or renal failure, arteriosclerosis, obliterans, obstructive thrombus, arterial embolus, Bürger-Grütz syndrome, acrocyanosis, chilblain, frostbite, prolactin-producing ovulation disorder, prolactin-producing pituitary tumor, puerperal galactoschesia, galactorrhea, distal hypertrophy, pituitary gigantism, mental illness, cerebrovascular diseases, tachycardia accompanied by sympathetic hypertonia, hyperaldosteronism, and diabetic complication.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB929205702A GB9205702D0 (en) | 1992-03-16 | 1992-03-16 | A new use of a quinazoline derivative |
| GB9205702.5 | 1992-03-16 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1993018769A2 WO1993018769A2 (en) | 1993-09-30 |
| WO1993018769A3 true WO1993018769A3 (en) | 1993-11-25 |
Family
ID=10712228
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/JP1993/000307 WO1993018769A2 (en) | 1992-03-16 | 1993-03-15 | A new use of quinazoline derivative |
Country Status (2)
| Country | Link |
|---|---|
| GB (1) | GB9205702D0 (en) |
| WO (1) | WO1993018769A2 (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2157208C2 (en) * | 1997-07-10 | 2000-10-10 | Институт органической и физической химии им. А.Е.Арбузова Казанского научного центра РАН | Preparation for treatment of freezing patients |
| SG11201700776XA (en) | 2014-08-01 | 2017-02-27 | Nuevolution As | Compounds active towards bromodomains |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0436157A1 (en) * | 1990-01-02 | 1991-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Quinazoline derivatives and their preparation |
| WO1993005035A1 (en) * | 1991-09-06 | 1993-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Quinazoline derivatives and their preparation |
-
1992
- 1992-03-16 GB GB929205702A patent/GB9205702D0/en active Pending
-
1993
- 1993-03-15 WO PCT/JP1993/000307 patent/WO1993018769A2/en active Application Filing
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0436157A1 (en) * | 1990-01-02 | 1991-07-10 | Fujisawa Pharmaceutical Co., Ltd. | Quinazoline derivatives and their preparation |
| WO1993005035A1 (en) * | 1991-09-06 | 1993-03-18 | Fujisawa Pharmaceutical Co., Ltd. | Quinazoline derivatives and their preparation |
Non-Patent Citations (3)
| Title |
|---|
| CARDIOVASCULAR DRUGS AND THERAPY vol. 4, no. S1, 1990, pages 73 - 84 C. COBO ET AL. ,V. COTO ET AL. , G.P. VYSSOULIS ET AL. 'EFFECTS OF KETANSERIN ON LEFT VENTRICULAR HYPERTROPHY IN HYPERTENSIVE PATIENTS, REGRESSION OF LEFT VENTRICULAR HYPERTROPHY AND SYSTOLIC FUNCTION IN HYPERTENSIVE PATIENTS DURING LONG-TERM TREATMENT WITH KETANSERIN, LEFT VENTRICULAR HYPERTROPHY REGRESSION AND FUNCTION CHANGES WITH KETANSERIN ...' * |
| GENERAL PHARMACOLOGY vol. 20, no. 6, 1989, pages 755 - 758 M. MIDOL-MONNET ET AL. 'STUDY ON THE MECHANISM OF 5-HT-INDUCED TACHYCARDIA IN THE PITHED RAT' * |
| JOURNAL OF CARDIOVASCULAR PHARMACOLOGY vol. 7, no. S7, 1985, pages S70 - S75 S. SAMAN ET AL. 'SEROTONIN AND THE HEART: EFFECTS OF KETANSERIN ON MYOCARDIAL FUNCTION, HEART RATE, AND ARRHYTHMIAS' * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO1993018769A2 (en) | 1993-09-30 |
| GB9205702D0 (en) | 1992-04-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PL332946A1 (en) | 1-phenylpyrazole compounds and their pharmaceutic application | |
| CA2432872A1 (en) | Pyrazole compounds useful as protein kinase inhibitors | |
| WO2000008048A3 (en) | Inhibitor of histone deacetylase | |
| EP0487745A4 (en) | Pyridine derivative with angiotensin ii antagonism | |
| EP0795548A4 (en) | Quinazoline derivatives and use thereof | |
| DK1063228T5 (en) | Cycloalkene derivatives, process for their preparation and use thereof | |
| AU3191995A (en) | Fused pyridazine compound | |
| WO2002072578A3 (en) | (homo) piperazine substituted quinolines for inhibiting the phosphorylation of kinases | |
| CA2160928A1 (en) | Compounds as pde iv and tnf inhibitors | |
| CA2080705A1 (en) | Substituted pyrimidines | |
| EP0555478A4 (en) | Pyrimidine derivative and medicine | |
| DE3572978D1 (en) | Piperazine compound as paf-antagonist | |
| WO2000068198A3 (en) | Heterosubstituted pyridine derivatives as pde 4 inhibitors | |
| NO941977L (en) | Indole derivatives, processes for their preparation, and medical use thereof | |
| KR950704314A (en) | 1,8-naphthyridin-2-one derivatives and methods of use thereof (1,8-NAPHTHYRIDIN-2-ONE DERIVATIVE AND USE THEREOF) | |
| EP0434057A3 (en) | Indolocarbazole derivatives, processes for their preparation and their use | |
| PT96404A (en) | METHOD FOR PREPARING NEW QUINAZOLINE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | |
| WO1993018769A3 (en) | A new use of quinazoline derivative | |
| EP0661274A1 (en) | Indane derivatives, processes for preparing the same and synthetic intermediate of the same | |
| WO2002062798A3 (en) | Salts of pyrimidine derivatives for use against coronary heart disease and atherosclerose | |
| WO2000003978A3 (en) | 2,5-substituted benzolsulfonylureas and thioureas, methods for the production thereof, use thereof and pharmaceutical preparations containing the same | |
| EP0201349A3 (en) | Tetrazole derivatives | |
| Foye et al. | Antiradiation compounds XVI: N‐heterocyclic aminoethyl disulfides and aminoethanethiosulfuric acids | |
| JPS5697226A (en) | Blood platelet coagulation inhibitor | |
| JPS5780321A (en) | Cardiotonic agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): CA JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): CA JP KR US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE |
|
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| 122 | Ep: pct application non-entry in european phase | ||
| NENP | Non-entry into the national phase |
Ref country code: CA |
|
| 122 | Ep: pct application non-entry in european phase |